New York 2025-2026 Regular Session

New York Assembly Bill A02145

Introduced
1/15/25  
Refer
1/15/25  
Report Pass
1/22/25  
Refer
1/22/25  

Caption

Permits prescription labels for mifepristone, misoprostol, and their generic alternatives to include the name of the prescribing health care practice instead of the name of the prescriber at the prescriber's request.

Summary

Bill A02145 amends the education law in New York to allow the prescription labels for mifepristone, misoprostol, and their generic alternatives to include the name of the dispensing health care practice instead of the individual prescriber's name. This change can be made at the request of the prescriber, thereby providing more flexibility in how prescriptions are labeled. The bill aims to enhance the confidentiality and privacy of prescribers while ensuring that patients receive their medications appropriately labeled.

Impact

The bill modifies existing education law regarding prescription labeling, specifically for certain medications related to reproductive health. By allowing the name of the health care practice to be displayed instead of the individual prescriber, it may impact how health care providers manage their practices and patient interactions. This could lead to a shift in prescribing practices, particularly in sensitive areas such as reproductive health, and may also influence how pharmacies handle these prescriptions.

Sentiment

The sentiment around Bill A02145 appears to be generally favorable, as indicated by the votes from the Assembly Higher Education Committee and the Assembly Rules Committee, both of which showed a majority in support of the bill. However, the presence of dissenting votes suggests that there are concerns among some members regarding the implications of the bill, particularly in relation to accountability and transparency in prescribing practices.

Contention

Notable points of contention include concerns from some lawmakers about the potential for reduced accountability when prescriptions do not include the prescriber's name. Critics argue that this could lead to challenges in tracking prescription practices and ensuring proper oversight. Supporters, on the other hand, emphasize the importance of protecting the privacy of health care providers, especially in sensitive areas of care such as reproductive health.

Companion Bills

NY S00036

Same As Permits prescription labels for mifepristone, misoprostol, and their generic alternatives to include the name of the prescribing health care practice instead of the name of the prescriber at the prescriber's request.

Previously Filed As

NY S00036

Permits prescription labels for mifepristone, misoprostol, and their generic alternatives to include the name of the prescribing health care practice instead of the name of the prescriber at the prescriber's request.

NY LD538

An Act to Amend Maine's Prescription Drug Labeling Law by Allowing the Removal of the Name of a Prescriber of Mifepristone, Misoprostol and Their Generic Alternatives

NY S04587

Provides the prescription label for mifepristone or misoprostol may include the address of the dispensing health care practice and shall include the address of the prescribing health care practice at the prescriber's request; provides that a health care prescriber shall inform a patient if such prescriber has included or has requested to include the name or address of the prescribing health care practice instead of the name of such prescriber on the prescription label when prescribing mifepristone or misoprostol.

NY A05285

Provides the prescription label for mifepristone or misoprostol may include the address of the dispensing health care practice and shall include the address of the prescribing health care practice at the prescriber's request; provides that a health care prescriber shall inform a patient if such prescriber has included or has requested to include the name or address of the prescribing health care practice instead of the name of such prescriber on the prescription label when prescribing mifepristone or misoprostol.

NY S08656

Provides that mifepristone or misoprostol may be dispensed without the name and address of the dispenser and patient included on the prescription label.

NY A10428

Provides that mifepristone or misoprostol may be dispensed without the name and address of the dispenser and patient included on the prescription label.

NY A10083

Provides that mifepristone or misoprostol may be dispensed without the name and address of the dispenser and patient included on the prescription label.

NY SB887

Providing for the use of the name of the prescriber's health care practice instead of the name of the prescriber on the prescription label for certain pharmaceuticals.

NY H7185

Provides that the prescription label for medication abortion prescription drugs may include the name of the dispensing healthcare practice instead of the name of the dispenser.

NY S2033

Provides that the prescription label for medication abortion prescription drugs may include the name of the dispensing healthcare practice instead of the name of the dispenser.

Similar Bills

No similar bills found.